Redeye: Heliospectra - H1 completed with solid order intake, high expectations for H2
Redeye concludes that Q2 revenues were weaker than expected, derived from short-term delays and order timing. However, with H1 showing a solid order intake, our and management’s expectations for H2 remain high. We reiterate our Base Case of SEK1.3.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/